000			03261nam a22003735i 4500
001			75958
003			ES-MaUEC
005			20230202101822.0
007			cr nn 008mamaa
008			130228s2013 xxu| s |||| 0|eng d
020			_a9781461465430
040			_aES-MaUEC
050		4	_aRC268.3 _bA687 2013 EB
100	1		_aAptsiauri, Natalia _0Local _984711
245	1	0	_aMHC Class I Antigens In Malignant Cells : _bImmune Escape And Response To Immunotherapy _cby Natalia Aptsiauri, Angel Miguel Garcia-Lora, Teresa Cabrera
260			_aNew York _bSpringer International Publishing _c2013
300			_a1 recurso en línea (VIII, 51 p.) 17 il., 14 il. col.
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	1		_aSpringerBriefs in Cancer Research _v6
520			_aAbnormal expression of MHC class I molecules in malignant cells is a frequent occurrenceÂ{u4A21}t ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches.Â{u1823}complete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy. Â{u0CA5}cise identification of the mechanism leading to MHC class I defects Â{u7A6C}l help to develop new personalized patient-tailored treatment protocols.Â{u4A25}re is significant new researchÂ{uFBA0}the prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data isÂ{u1DA1}ilable on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries thatÂ{u3A2F}wÂ{u4A25}Â{u0CAF}gression or regression of a tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact onÂ{u4974}ermining the final outcome of cancer immunotherapy.Â{u4A29}s SpringerBrief will presentÂ{u8BF7} MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy. Â{u0000}
942			_2lcc _cLE
988			_aEBOOK, EBSPRINGERrevisado
650		7	_aCáncer _xAspectos inmunológicos _9195595 _0comprobar BNE19923507443 _2embne
700	1		_aGarcia-Lora, Angel Miguel _984712 _0Local
700	1		_aCabrera, Teresa _984713 _0Local
830		0	_aSpringerBriefs in Cancer Research _v6 _9133181 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-1-4614-6543-0 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9781461465430
907			_a.b12815767 _b10-10-17 _c01-10-14
998			_am _a_alco _a_vill _b26-02-17 _cm _dz _eo _feng _gxxu _h0
945			_aRC268.3 A687 2013 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11545148 _z06-04-17
999			_c75958 _d75958 _x1